Investing.com - Yield10 Bioscience reported on Monday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Yield10 Bioscience announced earnings per share of $-0.710 on revenue of $111K. Analysts polled by Investing.com anticipated EPS of $-0.650 on revenue of $124.67K.
Yield10 Bioscience shares are down 63% from the beginning of the year and are trading at $2.730 , down-from-52-week-high.
Yield10 Bioscience follows other major Healthcare sector earnings this month
Yield10 Bioscience's report follows an earnings beat by J&J on October 18, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on November 1 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar